Precipio Stock Slips Post Q1 Earnings Despite Revenue Growth
PRPO's first-quarter 2026 sales are driven by pathology momentum, but CMS reimbursement cuts and higher spending squeeze margins and widen losses.
Zacks
The Zacks Analyst Blog NVIDIA, Mastercard, AbbVie, Waterstone and Precipio
AI demand and pipeline growth headline top Zacks stock reports on NVIDIA, Mastercard and AbbVie.
Zacks
Top Stock Reports for NVIDIA, Mastercard & AbbVie
NVIDIA, Mastercard and AbbVie headline Zacks' top stock reports, with AI growth, payment trends and drug launches in focus.
Zacks
Topline Capital Management LLC Purchases New Holdings in Precipio, Inc. $PRPO
Topline Capital Management LLC acquired a new position in Precipio, Inc. (NASDAQ:PRPO - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange...
MarketBeat
Precipio (NASDAQ:PRPO) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded Precipio from a "hold" rating to a "buy" rating in a research note on Saturday...
MarketBeat
The Zacks Analyst Blog AbbVie, The Coca-Cola, Chevron, ImmuCell and Precipio
AbbVie headlines today's top stock reports as Zacks highlights pharma recovery, resilient beverages and Chevron???s evolving energy outlook.
Zacks
Top Stock Reports for AbbVie, Coca-Cola & Chevron
ABBV, KO and CVX headline Zacks' top stock reports as analysts flag growth drivers, strategic moves and key headwinds shaping 2025 outlooks.
Zacks
Precipio Stock Up Following Solid Q3 Earnings and Improved Cash Flow
PRPO reports strong third-quarter 2025 results with higher revenue, positive cash flow and improved margins in core divisions.